Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.63 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760977 | 0.88 | OPRL1 (0.62) | OPRM1OPRL1OPRD1CHRM4MEN1 | |
| SCHEMBL5368096 | 0.85 | S1PR2 (0.49) | OPRM1OPRL1OPRD1CHRM4MEN1 | |
| SCHEMBL14282343 | 0.85 | POLB (0.61) | OPRM1OPRL1OPRD1MEN1KMT2A | |
| SCHEMBL5726893 | 0.85 | AKR1C3 (0.54) | OPRM1OPRL1OPRD1CHRM4MEN1 | |
| SCHEMBL2931546 | 0.85 | OPRM1 (0.47) | OPRM1OPRL1OPRD1CHRM4MEN1 | |
| SCHEMBL3133824 | 0.84 | OPRM1 (0.56) | OPRM1OPRL1OPRD1CHRM4MEN1 | |
| SCHEMBL3139132 | 0.84 | OPRL1 (0.61) | OPRM1OPRL1OPRD1CHRM4MEN1 | |
| SCHEMBL14282310 | 0.83 | S1PR2 (0.60) | OPRM1OPRL1CHRM4MEN1KMT2A | |
| SCHEMBL3594500 | 0.83 | OPRM1 (0.48) | OPRM1OPRL1OPRD1CHRM4MEN1 | |
| SCHEMBL23577913 | 0.82 | OPRL1 (0.53) | OPRM1OPRL1OPRD1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | claimed |
| CN-101448844-B | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists | HOFFMANN LA ROCHE | 2012-07-25 | — | — | CN | claimed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | claimed |
| CN-101448844-A | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists | HOFFMANN LA ROCHE (CH) | 2009-06-03 | — | — | CN | claimed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | claimed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | claimed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | claimed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | claimed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | claimed |
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| CN-101448844-B | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists | HOFFMANN LA ROCHE | 2012-07-25 | — | — | CN | disclosed |
| EP-2262792-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-12-22 | — | — | EP | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-1513836-B1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2006-05-03 | — | — | EP | disclosed |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| EP-1513835-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| EP-1513836-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003104226-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003104225-A1 | PIPERAZINYLACYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | OPRM1 3770/4885OPRL1 3885/4885OPRD1 3666/4885 |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | OPRM1 3240/4885OPRL1 2021/4885OPRD1 3164/4885 |
| US-20050176722-A1 | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | NR5A2, NR3C1, CBR1 | OPRM1 52/4885OPRL1 24/4885OPRD1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.